Former UMC chairman Mr. John Hsuan’s son, Yogi Hsuan, the president and founder of Meridigen Biotech, made a highest royalty deal this week in Taiwan. A technology license agreement related to “Collagen Scafford Antibody (CSA)” from ITRI. The license fee has reached TWD 100 million. The antibody can target to auto-immune diseases, such as Systemic Lupus Erythematosus (SLE), Multiple Sclerosis and Rheumatoid Arthritis (RA). Meridigen estimates to take 6 years with the cost of NTD 2 billion over pre-clinical and clinical trials.

Published on cnYES website, Feb. 25 2013.